Cargando…
Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab
INTRODUCTION: Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the preferred epitope or conformation of amyloid-β to target for treatment, and the mec...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095729/ https://www.ncbi.nlm.nih.gov/pubmed/25024748 http://dx.doi.org/10.1186/alzrt261 |
_version_ | 1782326085954830336 |
---|---|
author | Feinberg, Hadar Saldanha, José W Diep, Linnea Goel, Amita Widom, Angela Veldman, Geertruida M Weis, William I Schenk, Dale Basi, Guriqbal S |
author_facet | Feinberg, Hadar Saldanha, José W Diep, Linnea Goel, Amita Widom, Angela Veldman, Geertruida M Weis, William I Schenk, Dale Basi, Guriqbal S |
author_sort | Feinberg, Hadar |
collection | PubMed |
description | INTRODUCTION: Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the preferred epitope or conformation of amyloid-β to target for treatment, and the mechanism of action underlying immunotherapy. Bapineuzumab (humanized 3D6), a neo-epitope specific antibody recognizing amyloid-β1-5 with strong preference for an exposed Asp residue at the N-terminus of the peptide, has undergone advanced clinical testing for treatment of AD. METHODS: To gain further insight into the epitope conformation, we interrogated structural details of amino-terminal epitopes in amyloid-β using x-ray crystallography of 3D6Fab:amyloid-β complexes. Humanization of 3D6 was carried out using standard procedures integrating recombinant methods, sequence informatics, and homology modeling predictions to identify important mouse framework residues for retention in the finished humanized product. RESULTS: Here we report the crystal structure of a recombinant Fab fragment of 3D6 in complex with amyloid-β1-7 solved at 2.0 Å resolution. The N-terminus of amyloid-β is bound to 3D6 as a 3(10) helix. The amino-terminal Asp residue is buried deepest in the antibody binding pocket, with the Cβ atom of residue 6 visible at the entrance to the binding pocket near the surface of the antibody. We further evaluate homology model based predictions used to guide humanization of 3D6 to bapineuzumab, with actual structure of the Fab. The structure of the Fab:amyloid-β complex validates design of the humanized antibody, and confirms the amyloid-β epitope recognized by 3D6 as previously mapped by ELISA. CONCLUSIONS: The conformation of amyloid-β antigen recognized by 3D6 is novel and distinct from other antibodies recognizing N-terminal epitopes. Our result provides the first report demonstrating structural conservation of antigen contact residues, and conformation of antigen recognized, between the parent murine antibody and its humanized version. |
format | Online Article Text |
id | pubmed-4095729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40957292014-07-15 Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Feinberg, Hadar Saldanha, José W Diep, Linnea Goel, Amita Widom, Angela Veldman, Geertruida M Weis, William I Schenk, Dale Basi, Guriqbal S Alzheimers Res Ther Research INTRODUCTION: Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the preferred epitope or conformation of amyloid-β to target for treatment, and the mechanism of action underlying immunotherapy. Bapineuzumab (humanized 3D6), a neo-epitope specific antibody recognizing amyloid-β1-5 with strong preference for an exposed Asp residue at the N-terminus of the peptide, has undergone advanced clinical testing for treatment of AD. METHODS: To gain further insight into the epitope conformation, we interrogated structural details of amino-terminal epitopes in amyloid-β using x-ray crystallography of 3D6Fab:amyloid-β complexes. Humanization of 3D6 was carried out using standard procedures integrating recombinant methods, sequence informatics, and homology modeling predictions to identify important mouse framework residues for retention in the finished humanized product. RESULTS: Here we report the crystal structure of a recombinant Fab fragment of 3D6 in complex with amyloid-β1-7 solved at 2.0 Å resolution. The N-terminus of amyloid-β is bound to 3D6 as a 3(10) helix. The amino-terminal Asp residue is buried deepest in the antibody binding pocket, with the Cβ atom of residue 6 visible at the entrance to the binding pocket near the surface of the antibody. We further evaluate homology model based predictions used to guide humanization of 3D6 to bapineuzumab, with actual structure of the Fab. The structure of the Fab:amyloid-β complex validates design of the humanized antibody, and confirms the amyloid-β epitope recognized by 3D6 as previously mapped by ELISA. CONCLUSIONS: The conformation of amyloid-β antigen recognized by 3D6 is novel and distinct from other antibodies recognizing N-terminal epitopes. Our result provides the first report demonstrating structural conservation of antigen contact residues, and conformation of antigen recognized, between the parent murine antibody and its humanized version. BioMed Central 2014-06-02 /pmc/articles/PMC4095729/ /pubmed/25024748 http://dx.doi.org/10.1186/alzrt261 Text en Copyright © 2014 Feinberg et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Feinberg, Hadar Saldanha, José W Diep, Linnea Goel, Amita Widom, Angela Veldman, Geertruida M Weis, William I Schenk, Dale Basi, Guriqbal S Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab |
title | Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab |
title_full | Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab |
title_fullStr | Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab |
title_full_unstemmed | Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab |
title_short | Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab |
title_sort | crystal structure reveals conservation of amyloid-β conformation recognized by 3d6 following humanization to bapineuzumab |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095729/ https://www.ncbi.nlm.nih.gov/pubmed/25024748 http://dx.doi.org/10.1186/alzrt261 |
work_keys_str_mv | AT feinberghadar crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT saldanhajosew crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT dieplinnea crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT goelamita crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT widomangela crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT veldmangeertruidam crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT weiswilliami crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT schenkdale crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab AT basiguriqbals crystalstructurerevealsconservationofamyloidbconformationrecognizedby3d6followinghumanizationtobapineuzumab |